Shareholders vs. Monsanto and Bayer: From Activist Moms to the 2019 Investor Revolt Over Roundup

For years, activists used Monsanto’s annual shareholder meetings as a stage. Mothers concerned about pesticides and genetically engineered foods bought shares or obtained proxies so they could speak, urging executives to change direction. Shareholder proposals asked the company to report on risks from GMO contamination, label products, or assess pesticide impacts. Such proposals rarely won majority support, and management routinely recommended voting against them. For a long time, shareholder activism appeared to have little effect on the company’s strategy.

That changed after Bayer acquired Monsanto. In April 2019, amid mounting Roundup lawsuits and a falling share price, a majority of Bayer shareholders voted against ratifying management’s actions, a rare rebuke in German corporate history. This article explains how shareholder activism works, what happened at Monsanto and Bayer, and what the episode reveals about the ways investors, consumers, and courts can influence food and agriculture companies.

How did shareholders challenge Monsanto and Bayer? Through shareholder activism: investors filed proposals and voted to pressure the companies over GMO, pesticide, and legal risks. The 2019 Bayer vote was historic, with a majority of shareholders rejecting management’s handling of the Monsanto acquisition and its Roundup lawsuits. Investors acted mainly out of financial concern over falling share value, showing how commercial pressure, not just activism, can push companies.

What Is Shareholder Activism?

Shareholder activism is when investors use their ownership stakes to influence a company, by filing proposals, voting at annual meetings, and pressuring management on financial, environmental, or social issues. Owning shares in a public company gives investors certain rights: voting on directors and major decisions, attending annual meetings, asking questions, and, in the United States, submitting proposals for inclusion in the company’s proxy materials if they meet ownership and procedural thresholds. Proposals on environmental and social issues ask companies to disclose information, assess risks, or adopt policies. Even when proposals receive minority support, a significant vote can prompt dialogue with management. Activists sometimes buy a small number of shares or obtain proxies from sympathetic shareholders so they can speak at meetings, using the forum to address executives and attract media attention.

Large institutional investors, such as pension funds and asset managers, hold most shares in major companies, so their votes usually determine outcomes. Their decisions tend to focus on financial performance, governance, and risk, although many also consider environmental and social factors, particularly when those issues pose financial risks.

Activism at Monsanto

Before its acquisition, Monsanto faced recurring shareholder proposals and protests at its annual meetings in St. Louis. Proposals asked the company to report on the financial risks of genetically engineered crops, label products, or address pesticide impacts. Parents, farmers, and advocacy groups spoke during meetings about concerns over glyphosate residues and children’s health. The company responded that its products were safe and approved by regulators, and proposals typically received small percentages of votes. These efforts helped publicize concerns but did not change Monsanto’s core business, which centered on seeds, traits, and glyphosate-based herbicides.

What Happened in the 2019 Bayer Shareholder Revolt?

At Bayer’s 2019 annual meeting, a majority of shareholders voted to reject management’s handling of its Monsanto acquisition and the resulting Roundup cancer lawsuits, a rare and historic rebuke of a major company’s leadership. Bayer completed its $63 billion acquisition of Monsanto in 2018, aiming to become the world’s leading agricultural company. Weeks later, a California jury found Monsanto liable for failing to warn a groundskeeper that Roundup could cause cancer, and thousands of similar lawsuits followed. Fortune reported that at Bayer’s April 2019 annual general meeting, 55.5 percent of investors voted against “discharging,” or ratifying, the management board’s actions over the previous year, whereas German shareholders ordinarily discharge management with 90 percent or more; shareholders questioned whether management had adequately assessed liability risks before the acquisition. A Bayer spokesperson called the outcome “a new situation for us.” CNN Business coverage published by WRAL reported that Bayer then faced about 13,400 plaintiffs, that its shares had fallen more than 45 percent over the prior year, and that an analyst described the vote as unprecedented in Germany.

The vote did not legally remove management, and Bayer’s supervisory board backed the chief executive. But it signaled that investors held management accountable for the financial consequences of the Monsanto deal. In the following years, Bayer agreed to multibillion-dollar settlements of Roundup claims, stopped selling glyphosate-based Roundup to U.S. residential consumers, and pursued legal strategies culminating in the Supreme Court’s 2026 decision in Monsanto v. Durnell.

Why Did Financial Arguments Sway Investors?

Investors were moved less by ethics than by money: Bayer’s share price fell sharply after it bought Monsanto and faced billions in Roundup liabilities, so financial self-interest drove the shareholder backlash. The Bayer revolt shows a pattern seen across shareholder activism: investors respond most strongly when social or environmental concerns translate into financial risk. Years of activist speeches about health concerns had limited effect on Monsanto’s shareholders, but jury verdicts with large damages, thousands of pending lawsuits, and a falling share price affected investors directly. Advocates have learned to frame proposals in terms of risk to the company, such as litigation exposure, regulatory changes, reputational damage, and shifting consumer demand. Disclosure requests, such as asking a company to report on pesticide risks in its supply chain, are framed as helping investors assess these financial risks.

Lever	How it influences companies	Example
Shareholder votes and proposals	Signal investor concerns; prompt dialogue	Bayer 2019 vote against ratifying management
Litigation	Creates financial liability	Roundup verdicts and settlements
Regulation	Sets binding rules	EU neonicotinoid ban; state pesticide laws
Consumer demand	Shifts markets and supplier requirements	Retailers’ rBST-free milk policies
Public campaigns	Shape reputation and political agenda	GMO labeling campaigns

How Do Corporate Decisions Affect Public Health?

Corporate choices about products, marketing, and lobbying, known as commercial determinants of health, can shape public health, which is why holding companies accountable through investors and regulation matters. Public health researchers increasingly study how corporations shape health. A 2023 paper in The Lancet by Anna Gilmore and colleagues, part of a series on commercial determinants of health, defined them as the systems, practices, and pathways through which commercial actors drive health and equity, both positively and negatively, and examined how corporate practices such as marketing, lobbying, and shaping science can affect health. A 2021 review in Globalization and Health by Benjamin Wood and colleagues argued that public health research should pay more attention to corporate market power and proposed using economic frameworks that link market structure, corporate conduct, and outcomes to understand how dominant firms influence health. Shareholder engagement is one of the mechanisms these researchers discuss for influencing corporate behavior, along with regulation and civil society pressure.

Lessons From Tobacco and Other Industries

Public health researchers have long studied how industries respond to pressure over health harms. A 2013 analysis in The Lancet by Rob Moodie and colleagues examined tobacco, alcohol, and ultra-processed food and drink industries and concluded that there was no evidence that industry self-regulation or public-private partnerships were effective or safe, and that public regulation and market intervention were the only evidence-based mechanisms to prevent harms caused by unhealthy commodity industries. A 2023 paper in the same journal by Jennifer Lacy-Nichols and colleagues broadened the focus beyond a few harmful industries, examining how many kinds of commercial entities, including investors and financial institutions, shape health. These analyses suggest that shareholder engagement can complement, but rarely replace, regulation.

How Can Ordinary Investors Get Involved?

Individuals can influence companies by voting their shares (including through funds), supporting shareholder resolutions, investing in socially responsible funds, and engaging with the companies they own. Vote your proxies. Individual shareholders, including those holding shares through brokerage accounts, receive proxy materials and can vote on proposals.

Check fund voting records. Mutual funds and ETFs publicly report how they vote on shareholder proposals, allowing investors to choose funds whose voting aligns with their values.

Support shareholder advocacy groups. Nonprofit organizations file proposals and engage companies on environmental and health issues.

Ask questions. Shareholders can submit questions at annual meetings, many of which are now held virtually.

Combine approaches. Shareholder action is most effective alongside consumer choices, policy advocacy, and support for independent research.

How Shareholder Proposals Work in the United States

In the United States, shareholders who meet ownership and holding-period requirements can submit proposals to be included in a company’s proxy statement, allowing all shareholders to vote on them. Companies can seek to exclude proposals on certain grounds, such as relating to ordinary business operations, and the Securities and Exchange Commission reviews these requests. Most environmental and social proposals are advisory, meaning companies are not required to act even if a majority votes in favor, but strong support often prompts companies to respond. Rules governing eligibility and resubmission thresholds have changed over time, affecting how easily activists can bring issues to a vote. Proposals filed at food and agriculture companies have addressed pesticide use in supply chains, antibiotic use in livestock, deforestation, packaging, and nutrition.

German Corporate Governance and the Bayer Vote

The Bayer vote reflected a feature of German corporate law: each year, shareholders vote on whether to “discharge” the management board and supervisory board for the previous year’s conduct. Discharge does not release managers from legal liability, and a failed vote does not automatically remove anyone, but it is an important symbolic signal. Because German companies usually receive overwhelming support, a majority vote against discharge was extraordinary. Bayer’s supervisory board, which oversees management, publicly backed the chief executive after the vote, and he remained in office until 2023, when Bayer appointed a new chief executive amid continued pressure over the company’s performance and litigation.

What Happened Next at Bayer

After 2019, Bayer pursued a strategy of settling many Roundup claims while contesting others in court. In 2020 it announced a settlement program worth billions of dollars to resolve a large share of existing claims, though attempts to resolve future claims faced court obstacles. The company replaced glyphosate in U.S. residential Roundup products and continued defending glyphosate’s safety for agricultural use. Shareholders continued to press for a resolution to litigation uncertainty, and the company pursued appeals to the Supreme Court, culminating in the 2026 Durnell ruling that federal law preempts state failure-to-warn claims. The episode illustrates how litigation risk can shape a company’s strategy and its relationship with investors for years.

Activists Who Spoke at Monsanto Meetings

Parents who spoke at Monsanto’s annual meetings often described personal experiences, such as children’s health problems they attributed to diet or pesticides, and asked executives to change course. These appeals generated media coverage and helped build a movement around food transparency, contributing to campaigns for GMO labeling and pesticide restrictions. While individual anecdotes cannot establish causation, they highlighted public concerns that later appeared in lawsuits, legislative debates, and consumer markets. Such activism shows how shareholder meetings can serve as platforms for public voices, even when votes do not change policy.

Key Facts at a Glance

Bayer completed its $63 billion acquisition of Monsanto in 2018. At Bayer’s April 2019 annual meeting, 55.5 percent of votes cast opposed ratifying the management board’s actions, compared with typical approval of 90 percent or more in Germany. At the time, Bayer faced about 13,400 Roundup plaintiffs and its shares had fallen more than 45 percent over the previous year. Public health research identifies commercial determinants of health and finds that regulation and market intervention, rather than industry self-regulation, are the evidence-based tools for preventing harms from unhealthy commodity industries.

Responsible Investing Options

Investors who want their money to reflect health or environmental values have several options. Some funds screen out companies in certain industries, such as tobacco or pesticides. Others use environmental, social, and governance (ESG) ratings to tilt portfolios toward companies with better scores, though rating methods vary widely. Some funds focus on shareholder engagement, filing proposals and voting actively on environmental and social issues. Investors should review fund holdings, voting records, and fees, since labels can be vague. Research on whether such approaches affect corporate behavior or financial returns has produced mixed results, and the field remains debated.

Common Myths

“Shareholders can force companies to change on any issue.” Most environmental and social proposals are advisory, and large institutional investors usually determine outcomes.

“The Bayer vote removed its CEO.” The vote was non-binding; the CEO remained in office until 2023.

“Activist speeches have no effect.” They rarely change votes directly but can raise public awareness and influence later policy debates.

“Investor pressure replaces regulation.” Evidence suggests regulation remains essential for preventing health harms from commercial products.

Key Terms

Proxy statement: A document companies send shareholders before meetings, including proposals to be voted on.

Shareholder proposal: A resolution submitted by a shareholder for a vote at the annual meeting.

Discharge vote: In Germany, an annual vote on ratifying the actions of management and supervisory boards.

Stewardship: How institutional investors engage with companies and vote shares.

Commercial determinants of health: How commercial actors and practices influence health.

The Bottom Line

Shareholder activism at Monsanto gave parents and advocates a platform but rarely changed policy, because large institutional investors controlled outcomes and focused on financial performance. At Bayer, financial consequences of Roundup litigation produced an unprecedented 2019 rebuke, showing that investors respond most strongly when risks hit share prices. Public health research suggests that investor pressure can complement but not replace regulation in addressing harms from commercial products. Individuals can participate by voting proxies, choosing funds aligned with their values, and supporting shareholder advocacy alongside policy engagement and informed consumer choices.

Further Reading

News coverage of Bayer’s 2019 annual meeting describes the vote and its context. The Lancet’s 2023 series on commercial determinants of health explains how corporations shape health and what tools can address harms. Fund companies publish proxy voting records, and the SEC provides information on shareholder proposals and proxy rules.

Looking Ahead

Shareholder engagement on food and agriculture issues continues to evolve. Investors increasingly ask companies about climate risks in supply chains, pesticide reduction, antibiotic use, and nutrition. At the same time, political debates over ESG investing have made some asset managers more cautious about environmental and social voting. Litigation outcomes, such as the 2026 Durnell decision, and regulatory developments will shape the risks investors weigh. For people concerned about food and health, understanding how investors influence companies adds another tool to the broader set of approaches for change.

A Balanced View

Shareholder activism is neither a cure-all nor meaningless. It gives voice to concerns, can prompt disclosure, and sometimes changes corporate behavior when backed by large investors or financial risk. It is limited by the concentration of voting power in institutional investors, the advisory nature of most proposals, and investors’ primary focus on returns. The Monsanto and Bayer story shows both sides: years of activism raised awareness without changing policy, while litigation losses produced a dramatic investor response. Combining shareholder engagement with regulation, litigation, research, and consumer action offers the most realistic path for those seeking change in food and agriculture.

Questions Shareholders Can Ask Companies

How does the company assess and disclose litigation risks from its products? What steps is it taking to reduce health and environmental impacts of pesticides or other products? How does it oversee scientific research it funds? How do executive incentives account for long-term risks? How does the board oversee product safety? Asking such questions at meetings or through investor engagement can encourage transparency and accountability, even when proposals do not pass.

Investor Concerns About Agriculture Risks

Beyond litigation, investors in agricultural companies weigh risks such as regulatory changes to pesticides, consumer demand for organic and non-GMO products, climate impacts on crop production, pest and weed resistance that can erode product value, and reputational issues. Analysts track how companies disclose and manage these risks. For agrochemical firms, regulatory decisions in major markets, such as the European Union’s restrictions on certain pesticides or U.S. EPA reviews, can affect product portfolios. Shareholder questions increasingly address these issues, reflecting a recognition that health and environmental concerns can become financial ones.

How Parents Can Get Involved

Parents concerned about food and pesticides have many avenues beyond shareholder meetings. They can participate in school wellness committees, advocate for integrated pest management on school grounds, support local and state policy initiatives, and engage with food companies through consumer feedback. Joining organizations that track pesticide policy or food safety provides information and collective voice. For those who own shares, voting proxies thoughtfully and asking fund managers about their voting policies adds another channel. Combining approaches tends to be more effective than relying on any single one.

Key Facts About Bayer’s Litigation Path

After the first jury verdict in August 2018, Bayer faced tens of thousands of Roundup claims. It announced a settlement program in 2020 covering a large share of existing claims, while some cases continued to trial with mixed results. The company argued that federal pesticide law preempted state failure-to-warn claims, an argument rejected by several appeals courts but ultimately accepted by the Supreme Court in Monsanto v. Durnell in June 2026. Throughout this period, Bayer’s share price and investor sentiment were closely tied to litigation developments, illustrating how legal risks can dominate a company’s financial story.

For investors, the case became a prominent example of how acquisition due diligence must account for product liability exposure.

Comparing Activism Across Companies

Shareholder activism on food and agriculture has targeted many companies beyond Monsanto and Bayer. Investors have filed proposals at fast-food chains on antibiotic use in meat supply chains, at food manufacturers on sugar and nutrition, at grocery retailers on pesticides affecting pollinators, and at beverage companies on plastic packaging. Some campaigns achieved policy changes after negotiations, with proposals withdrawn when companies agreed to act. These examples show that engagement can work when investors, advocates, and companies find common ground, particularly when changes also reduce business risks or meet consumer demand.

Tracking which proposals succeed helps advocates focus on approaches with the best chance of real-world impact.

Why German Votes Drew International Attention

Bayer’s 2019 vote attracted global coverage because it was rare for shareholders of a major company to publicly rebuke management so decisively, and because the trigger was a U.S. litigation wave over a widely used herbicide. The vote linked American courtroom verdicts to European corporate governance and global investor sentiment. Analysts discussed whether Bayer might break up its pharmaceutical and agricultural businesses, and governance experts debated whether the deal had been adequately scrutinized. The episode became a case study in business schools on merger risk assessment and the financial consequences of product liability.

It also showed how health and environmental controversies can quickly become boardroom issues.

Practical Takeaways

If you own shares directly, read proxy materials and vote, including on environmental and social proposals. If you invest through funds, check whether your fund offers voting choice programs and review its voting record. Consider funds aligned with your values while comparing costs and performance. Support organizations that engage companies on issues you care about. And remember that shareholder action works best alongside participation in policy processes and informed consumer decisions, since regulation remains the most powerful tool for preventing harm.

How Annual Meetings Work Today

Annual shareholder meetings have changed since the era when activists traveled to Monsanto’s St. Louis headquarters to speak. Many companies, including Bayer, moved to virtual or hybrid meetings, especially after 2020, where shareholders submit questions in advance or online. Critics argue virtual formats can limit spontaneous questions and allow companies to filter difficult issues, while supporters note they make participation easier for shareholders worldwide. Investors and advocacy groups have pressed for rules ensuring meaningful opportunities to ask questions and receive answers. For activists, these changes shape how shareholder meetings can serve as platforms for raising health and environmental concerns.

Lessons for Companies

For companies, the Monsanto and Bayer story suggests that dismissing public concerns can carry long-term costs. Engaging seriously with shareholder questions, disclosing risks transparently, investing in independent research, and adapting products in response to evidence and demand can reduce reputational and legal risks. The rapid transformation of investor sentiment after 2018 showed that issues long raised by activists can become material financial concerns, and that boards should consider such issues before they escalate.

Proactive engagement can turn potential conflicts into opportunities for improvement.

Where to Find Information

Company proxy statements and annual reports, available on company websites and through securities regulators, list proposals, voting results, and risk disclosures. Fund companies publish proxy voting records and stewardship reports. Shareholder advocacy organizations track proposals on environmental and social topics and publish annual reviews. News outlets cover major annual meetings, especially when votes signal investor discontent. Using these sources, individuals can follow how companies and investors respond to health and environmental concerns over time.

Following these sources over several years reveals patterns in how companies respond to investor concerns, which issues gain traction, and how voting support for environmental and health proposals rises or falls with public attention, litigation, and regulatory developments affecting food and agriculture companies around the world.

Key Lessons in Brief

Shareholder speeches raise awareness but rarely change votes on their own. Financial risk, such as litigation exposure, moves institutional investors most strongly. German discharge votes are symbolic but closely watched signals of investor confidence. Regulation remains the most effective tool for preventing health harms, with investor engagement as a complement. And individual investors can participate through proxy voting and fund choices.

Together, these lessons suggest that people seeking change in food and agriculture benefit from understanding how corporate governance works and where their influence as shareholders, consumers, and citizens can matter most over time.

Understanding these mechanisms makes it easier to evaluate news about shareholder votes and corporate responses, and to decide where personal action as an investor, consumer, or voter can have the most meaningful effect on food and agricultural practices that affect public health in communities across the country and around the world today.

Frequently Asked Questions

What is shareholder activism?

Shareholder activism is when investors use their ownership of a company’s stock to push for change. They can file formal proposals, vote at annual meetings, and publicly pressure management on financial, environmental, social, or governance issues. Because shareholders ultimately own the company, organized investors can influence decisions, leadership, and corporate behavior, sometimes more effectively than outside critics.

What was the 2019 Bayer shareholder revolt?

At Bayer’s 2019 annual meeting, a majority of shareholders voted against approving management’s performance, a historic rebuke rarely seen at a major company. Investors were angry about Bayer’s 2018 acquisition of Monsanto, which saddled it with tens of thousands of Roundup cancer lawsuits and caused its share price to plunge. The vote was non-binding but deeply symbolic.

Why did investors turn against Bayer’s Monsanto deal?

Mainly for financial reasons. After buying Monsanto for about $63 billion in 2018, Bayer inherited massive Roundup litigation, and its market value fell dramatically as juries awarded large verdicts. Shareholders concluded that management had underestimated the legal risks, so their revolt was driven by lost value and self-interest as much as by concern over the products themselves.

Can shareholder pressure change how companies behave?

Yes, to a degree. Shareholder votes and proposals can pressure companies to change leadership, strategy, disclosure, or practices, especially when tied to financial performance, as the Bayer case showed. Activism rarely transforms a company overnight, but sustained investor pressure, combined with regulation and public scrutiny, can influence corporate decisions on issues including health and the environment.

How can an ordinary person influence a company they invest in?

Individual investors can vote their shares at annual meetings, including on shareholder resolutions, and many funds let investors direct or follow voting policies. People can also choose socially responsible or ESG-focused funds, support advocacy groups that file resolutions, and communicate concerns to companies. While one small shareholder has limited power, collective action among many investors can be influential.

References

1. Gilmore AB, Fabbri A, Baum F, et al. Defining and conceptualising the commercial determinants of health. Lancet. 2023;401(10383):1194–1213. PMID 36966782
2. Wood B, Williams O, Baker P, et al. The influence of corporate market power on health: exploring the structure-conduct-performance model from a public health perspective. Globalization and Health. 2021;17(1):41. PMID 33823900
3. Fortune. Bayer CEO Has 9 Months to Overcome Shareholders’ Extraordinary Rebuke of His Monsanto Deal. April 30, 2019. fortune.com
4. WRAL (CNN Business). Bayer’s Roundup legal costs mount. 2019. wral.com
5. Moodie R, Stuckler D, Monteiro C, et al. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet. 2013;381(9867):670–679. PMID 23410611
6. Lacy-Nichols J, Nandi S, Mialon M, et al. Conceptualising commercial entities in public health: beyond unhealthy commodities and transnational corporations. Lancet. 2023;401(10383):1214–1228. PMID 36966783

Last updated: October 6, 2026